Dry Eye Syndrome Market Research Report- Forecast to 2027

Global Dry Eye Syndrome Market research report, by type (evaporative, aqueous), by diagnosis (schirmer test, eye exam), treatment (nutritional supplements, surgery), distribution channel (hospital pharmacies) end user (hospitals) - global forecast till 2027

ID: MRFR/Pharma/4139-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Global dry eye syndrome market is expected to advance with an approximate CAGR of 6.6% during the forecast period.


Tears provide lubrication, limits the risks of eye infections, washes away the foreign matter, thus, are helpful in keeping the surface of the eyes smooth and clear. Dry eye syndrome is a medical condition in which eyes’ lubrication is hindered by the unavailability of tears. Under normal condition, during excessive production, tears flow into the small drainage ducts of the inner corners of the eyes, followed by draining back into the nose. Sometimes when the production of tears and drainage is not balanced, it can result into dry eye syndrome. Eye redness, sensitivity to light, watery eyes, eye fatigue are some of the common symptoms of the disease. Increasing geriatric population, rising prevalence of diseases like diabetes, rheumatoid arthritis, and others are estimated to be the major drivers for the market growth. According to the World Health Organization in 2016, approximately 422 million adults were globally affected by diabetes in 2014, as compared to 108 million in the 1980’s. Moreover, in 2014, it was estimated that the global prevalence of diabetes was estimated to be around 8.5%. Additionally, rising per capita healthcare expenditure, and changing lifestyle boosts the market. However, factors like stringent FDA drug approvals, lack of skilled ophthalmologists, and low per capita healthcare expenditure in the middle and low income countries are restraining the market.  


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government And Private Laboratories

  • Research And Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1: Global Dry Eye Syndrome Share, By Region


 Dry Eye Syndrome


Sources: WHO, Mayo Foundation for Medical Education and Research, National Health Service, National Eye Institute, Australian Institute of Health and Welfare, annual reports, press release, white paper, and company presentation


Segmentation


The global dry eye syndrome is segmented on the basis of the type, diagnosis, treatment, distribution channel and end user.


On the basis of the type, the market is segmented into evaporative dry eye syndrome aqueous dry eye syndrome, and others. On the basis of the diagnosis, the market is categorized into Schirmer test, eye exam, and others.  On the basis of the treatment, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, anti-inflammatory drugs segments, surgery, and others. The lubricant eye drops segment is sub-segmented into oily tear eye drops, ointments, preservative-free drops, and others. The anti-inflammatory drugs segments segement is sub-segmented into tetracyclines, corticosteroids, and others. The surgery segment is sub-segmented into punctal occlusion, intense pulsed light therapy, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others.  On the basis of the end users, the market is segmented into hospitals, clinics, home care, and others.


Key Players in dry eye syndrome market


The key players for the global dry eye syndrome are Allergan (Republic of Ireland), Novartis AG (Switzerland), Otsuka Pharmaceutical Co. Ltd. (Japan), Valent Pharmaceuticals (Canada), Johnson & Johnson Vision (U.S.), Acadia Pharmaceutical (U.S.), Allostera Pharma (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT pharmaceuticals (New Zealand), Novaliq GmBh (Germany), Auven therapeutics (U.S.), and others.


Research Methodology
Dry Eye Syndrome  Research


Sources: WHO, Mayo Foundation for Medical Education and Research, National Health Service, National Eye Institute, Australian Institute of Health and Welfare, annual reports, press release, white paper, and company presentation


Regional Analysis


America dominates the global dry eye syndrome market. This can be attributed to the presence of a well-developed healthcare sector and a large patient population. Moreover, increasing healthcare expenditure boosts the growth of the American market. Additionally, the presence of the major market players like Johnson & Johnson Vision, Auven therapeutics, Acadia Pharmaceutical, and others within the region fuels the market growth.


Europe is the second largest dry eye syndrome market owing to increasing availability of funds for research, a well-developed healthcare sector, huge patient pool and growing geriatric population. According to the Saga in 2017, approximately 20% of people living in the U.K suffer from dry eye syndrome. Moreover, it was estimated that one in three people who age 65 or more within the region are diagnosed with this disease.


Asia Pacific is the fastest growing region for the market due to the presence of economies like India, China, Australia, and others. Moreover, huge patient population, rising healthcare expenditure boosts the market growth. According to the Australian Institute of Health and Welfare, the total Australian health expenditure from 2015 to 2016 was estimated to be about USD 170.4 billion.


The Middle East & Africa has the least share in the global dry eye syndrome due to the presence of poor economies, low per capita healthcare expenditure, stringent government policies, especially within the African region. The Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure by the developed economies like Dubai, Kuwait, Dubai, and others.


 



Frequently Asked Questions (FAQ) :


The outlook of the global dry eye syndrome market looks flourishingly growing.

The global dry eye syndrome market is projected to grow at approximately 6.6% CAGR during forecast period (2017-2023).

North America holds the largest share in the global dry eye syndrome market followed by Europe and Asia Pacific, respectively.

SORIN Group (Europe), LEPU MEDICAL (UK), MEDICO S.p.A. (Europe), Abbott. (US), Medtronic (US), Boston Scientific Corporation (US), OSCOR Inc. (US), and BIOTRONIK (Germany), are some of the major players operating in the dry eye syndrome market.

TABLE OF CONTENT


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Dry Eye Syndrome Market, by Type

6.1 Introduction

6.2 Evaporative Dry Eye Syndrome

Market Estimates & Forecast, 2020 – 2027

6.3 Aqueous Dry Eye Syndrome

Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Dry Eye Syndrome Market, by Diagnosis

7.1 Introduction

7.2 Schirmer Test

Market Estimates & Forecast, 2020 – 2027

7.3 Eye Exam

Market Estimates & Forecast, 2020 – 2027

7.4 Others

Chapter 8. Global Dry Eye Syndrome Market, by Treatment

8.1 Introduction

8.2 Nutritional Supplements

Market Estimates & Forecast, 2020 – 2027

8.3 Serum Eye Drops

Market Estimates & Forecast, 2020 – 2027

8.4 Lubricant Eye Drops

Market Estimates & Forecast, 2020 – 2027

8.4.1 Oily Tear Eye Drops

8.4.2 Ointments

8.4.3 Preservative-Free drops

8.4.4 Others

8.5 Anti-Inflammatory Drugs Segments

Market Estimates & Forecast, 2020 – 2027

8.5.1 Tetracyclines

8.5.2 Corticosteroids

8.5.3 Others

8.6 Surgery

Market Estimates & Forecast, 2020 – 2027

8.6.1 Punctal Occlusion

8.6.2 Intense Pulsed Light Therapy

8.6.3 Others

8.7 Others

Chapter 9 Global Dry Eye Syndrome Market, by Distribution Channel

9.1 Introduction

9.2 Hospital pharmacies

Market Estimates & Forecast, 2020 – 2027

9.3 Retail pharmacies

Market Estimates & Forecast, 2020 – 2027

9.4 Online Pharmacies

Market Estimates & Forecast, 2020 – 2027

9.5 Others

Chapter 10 Global Dry Eye Syndrome Market, by End User

10.1 Introduction

10.2 Hospitals

Market Estimates & Forecast, 2020 – 2027

10.3 Clinics

Market Estimates & Forecast, 2020 – 2027

10.4 Home Care

Market Estimates & Forecast, 2020 – 2027

10.5 Others

Chapter 11. Global Dry Eye Syndrome Market, by Region

11.1 Introduction

11.2 America

11.2.1 North America

11.2.1.1 U.S.

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Oman

11.5.4 Kuwait

11.5.5 Qatar

11.5.6 Rest of the The Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 Allergan

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 Novartis AG

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Otsuka Pharmaceutical Co. Ltd.

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Valent Pharmaceuticals

13.4.1 Company Overview

13.4.2 Product/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Johnson and Johnson Vision

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Acadia Pharmaceutical

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 Allostera Pharma

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 I-Med Pharma Inc.

13.8.1 Overview

13.8.2 Product Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Santen Pharmaceuticals Co. Ltd.

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 AFT pharmaceuticals

13.10.1 Overview

13.10.2 Product Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Novaliq GmBh

13.11.1 Overview

13.11.2 Product Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

13.12 Auven therapeutics

13.12.1 Overview

13.12.2 Product Overview

13.12.3 Financials

13.12.4 Key Developments

13.12.5 SWOT Analysis

13.13 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Dry Eye Syndrome Industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Dry Eye Syndrome Industry Synopsis, 2020 – 2027

Table 2 Global Dry Eye Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Dry Eye Syndrome Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 8 Global Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 9 North America Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 10 North America Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 11 North America Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 12 North America Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 13 North America Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 14 US Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 15 US Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 16 US Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 17 US Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 18 US Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 19 Canada Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 20 Canada Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 21 Canada Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 22 Canada Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 23 Canada Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 24 South America Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 25 South America Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 South America Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 27 South America Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 28 South America Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 29 Europe Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 30 Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 31 Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 32 Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 33 Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 34 Western Dry Eye Syndrome Europe Market by Type, 2020 – 2027, (USD Million)

Table 35 Western Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 36 Western Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 37 Western Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 38 Western Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 39 Eastern Europe Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 40 Eastern Europe Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 41 Eastern Europe Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 42 Eastern Europe Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 43 Eastern Europe Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 44 Asia Pacific Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 45 Asia Pacific Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 46 Asia Pacific Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 47 Asia Pacific Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 48 Asia Pacific Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 49 The Middle East & Africa Dry Eye Syndrome Market by Type, 2020 – 2027, (USD Million)

Table 50 The Middle East & Africa Dry Eye Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 51 The Middle East & Africa Dry Eye Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 52 The Middle East & Africa Dry Eye Syndrome Market by Distribution Channel, 2020 – 2027, (USD Million)

Table 53 The Middle East & Africa Dry Eye Syndrome Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Dry Eye Syndrome Market

Figure 3 Segmentation Market Dynamics for Global Dry Eye Syndrome Market

Figure 4 Global Dry Eye Syndrome Market Share, by Type 2020

Figure 5 Global Dry Eye Syndrome Market Share, by Diagnosis 2020

Figure 6 Global Dry Eye Syndrome Market Share, by Treatment 2020

Figure 7 Global Dry Eye Syndrome Market Share, by Distribution Channel 2020

Figure 8 Global Dry Eye Syndrome Market Share, by End User, 2020

Figure 9 Global Dry Eye Syndrome Market Share, by Region, 2020

Figure 10 North America Dry Eye Syndrome Market Share, by Country, 2020

Figure 11 Europe Dry Eye Syndrome Market Share, by Country, 2020

Figure 12 Asia Pacific Dry Eye Syndrome Market Share, by Country, 2020

Figure 13 The Middle East & Africa Dry Eye Syndrome Market Share, by Country, 2020

Figure 14 Global Dry Eye Syndrome Market: Company Share Analysis, 2020 (%)

Figure 15 Allergan: Key Financials

Figure 16 Allergan: Segmental Revenue

Figure 17 Allergan: Geographical Revenue

Figure 18 Novartis AG: Key Financials

Figure 19 Novartis AG: Segmental Revenue

Figure 20 Novartis AG: Geographical Revenue

Figure 21 Otsuka Pharmaceutical Co. Ltd.: Key Financials

Figure 22 Otsuka Pharmaceutical Co. Ltd.: Segmental Revenue

Figure 23 Otsuka Pharmaceutical Co. Ltd.: Geographical Revenue

Figure 24 Valent Pharmaceuticals: Key Financials

Figure 25 Valent Pharmaceuticals: Segmental Revenue

Figure 26 Valent Pharmaceuticals: Geographical Revenue

Figure 27 Johnson and Johnson Vision: Key Financials

Figure 28 Johnson and Johnson Vision: Segmental Revenue

Figure 29 Johnson and Johnson Vision: Geographical Revenue

Figure 30 Acadia Pharmaceutical: Key Financials

Figure 31 Acadia Pharmaceutical: Segmental Revenue

Figure 32 Acadia Pharmaceutical: Geographical Revenue

Figure 33 Allostera Pharma: Key Financials

Figure 34 Allostera Pharma: Segmental Revenue

Figure 35 Allostera Pharma: Geographical Revenue

Figure 36 I-Med Pharma Inc.: Key Financials

Figure 37 I-Med Pharma Inc.: Segmental Revenue

Figure 38 I-Med Pharma Inc.: Geographical Revenue

Figure 39 Santen Pharmaceuticals Co. Ltd.: Key Financials

Figure 40 Santen Pharmaceuticals Co. Ltd.: Segmental Revenue

Figure 41 Santen Pharmaceuticals Co. Ltd.: Geographical Revenue

Figure 42 AFT pharmaceuticals: Key Financials

Figure 43 AFT pharmaceuticals: Segmental Revenue

Figure 44 AFT pharmaceuticals: Geographical Revenue

Figure 45 Novaliq GmBh: Key Financials

Figure 46 Novaliq GmBh: Segmental Revenue

Figure 47 Novaliq GmBh: Geographical Revenue

Figure 48 Auven therapeutics: Key Financials

Figure 49 Auven therapeutics: Segmental Revenue

Figure 50 Auven therapeutics: Geographical Revenue